Clinical Trial

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Study acronym: P+R-ICE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 15, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, multicentre, randomised phase II trial in relapsed or refractory diffuse large B-cell lymphoma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-02-02; most recent amendment 2026-05-14.
Status change: Recruiting → Active, Not Recruiting 2024-12-04
Status change: Not Yet Recruiting → Recruiting 2022-11-02
Trial Details
NCT Number NCT05221645
Lead Sponsor University of Southampton
Collaborators: Merck Sharp & Dohme LLC
Conditions Diffuse Large B Cell Lymphoma
Enrollment 65 participants
Start Date 2022-06-27
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-15